Pharma’s fight against superbugs is still underfunded
Over the last two years, the drug industry has only narrowly increased its work in anti-infective science, according to a new report, an effort easily dwarfed by the need for new medicines.
As STAT’s Ed Silverman reports, the Access to Medicine Foundation saw “signs of progress” in its latest look at the industry’s work in antibiotics, but nothing that would change the tide in the mounting problem of drug-resistant infections.
Perhaps most alarming is who’s funding the new ideas. According to the report, of the 138 treatments in the industry’s pipeline, only nine are considered innovative. The majority of those are being developed by small biotech companies, which have in the past struggled to find sustainable business models that might bring those drugs to fruition.
Read more.
As STAT’s Ed Silverman reports, the Access to Medicine Foundation saw “signs of progress” in its latest look at the industry’s work in antibiotics, but nothing that would change the tide in the mounting problem of drug-resistant infections.
Perhaps most alarming is who’s funding the new ideas. According to the report, of the 138 treatments in the industry’s pipeline, only nine are considered innovative. The majority of those are being developed by small biotech companies, which have in the past struggled to find sustainable business models that might bring those drugs to fruition.
Read more.
No hay comentarios:
Publicar un comentario